Home | About | Journals | Submit | Contact Us | Français |

**|**HHS Author Manuscripts**|**PMC2874964

Formats

Article sections

Authors

Related links

Antivir Ther. Author manuscript; available in PMC 2010 May 24.

Published in final edited form as:

Antivir Ther. 2009; 14(3): 459–464.

PMCID: PMC2874964

NIHMSID: NIHMS201459

Harel Dahari,^{1,}^{*} Emi Shudo,^{2} Scott J. Cotler,^{1} Thomas J. Layden,^{1} and Alan S. Perelson^{2}

See other articles in PMC that cite the published article.

Patients infected with hepatitis C virus (HCV) who respond to treatment with interferon-α plus ribavirin exhibit biphasic or triphasic viral load declines. While the rapid first phase is indicative of the effectiveness of therapy in blocking viral production, ε, the slope of the final phase, λ, i.e., the second phase in biphasic declines and the third phase in triphasic declines, depends on the infected-cell loss rate, δ. Further, in standard models λ is approximately εδ, when the viral-clearance rate c>>δ as has been previously estimated.

The relationship among ε, δ, λ and the baseline fraction of HCV-infected hepatocytes, π, was investigated in a model that includes proliferation of hepatocytes.

We find that λ is not proportional to ε but rather obeys complex relationship that can lead to dramatic increases in estimates of δ as ε increases. In particular, when ε<99%, λ moderately underestimates δ in patients with a small π, whereas δ may be up to 10-fold larger than λ in patients with a large π. Interestingly, when ε>99%, δ~λ, regardless of π.

Our results indicate that under therapy achieving <2 log reduction in viral load (ε<99%), previously estimated δ values may represent only a minimal estimate of the infected-cell loss rate. Moreover, combining interferon-α with new antiviral agents to achieve ε>99% should allow for a more accurate estimate of δ in HCV-RNA kinetic studies. This may be important when using viral kinetics to estimate the impact of the immune response on viral elimination and the attainment of sustained virological response.

Approximately 200 million persons are infected with hepatitis C virus (HCV) worldwide and 20% – 30% will likely progress to cirrhosis [1]. Antiviral therapy consisting of pegylated interferon-α (PEG-IFN) and ribavirin achieves sustained virologic response rates (SVR) of ~50% in patients with HCV genotype-1 [2, 3]. There is a compelling need to better understand HCV infection and antiviral therapy in order to optimize the use of interferon-α (IFN) and ribavirin as well as new agents that are in development.

Mathematical models of HCV infection indicate that the final slope of HCV-RNA decay represents the rate of infected cell loss, δ, when the drug effectiveness, ε, is close to 1 [4-6]. However, in models that incorporate the possibility of de-novo hepatocyte infection during therapy or infected cell proliferation this may not be the case as both de novo infection and proliferation of infected cells during therapy reduce the rate of infected cell loss. Therefore, determining the conditions needed in order to estimate, with confidence, δ from the final slope of HCV-RNA decay is the main goal of this communication. To accomplish this goal we explore the relationship among drug effectiveness, the final phase decay slope, the loss rate of infected cells, and the fraction of hepatocytes that are HCV infected at the start of therapy (π) in the context of a kinetic model that allows proliferation of uninfected and infected hepatocytes [5]. The equations describing the dynamics of HCV infection and treatment in this model involve uninfected hepatocytes (*T*), infected hepatocytes (*I*) and virus (*V*), are

$$\begin{array}{c}\frac{dT}{dt}=s+{r}_{T}(1-\frac{T+I}{{T}_{\mathrm{max}}})-{d}_{T}T-(1-\eta )\beta VT\hfill \\ \frac{dI}{dt}=(1-\eta )\beta VT+{r}_{I}I(1-\frac{T+I}{{T}_{\mathrm{max}}})-\delta I\hfill \\ \frac{dV}{dt}=(1-\epsilon )pI-cV.\hfill \end{array}$$

(1)

Uninfected (*T*) and infected hepatocytes (*I*) can proliferate with maximum proliferation rates *r _{T}* and

We recently introduced the notion of critical drug efficacy, ε_{c}, for the treatment of HCV [5] and hepatitis B virus [9] analogous to previous efforts in the field of human immunodeficiency virus treatment [10, 11]. For the model given by Eq. (1)

$${\epsilon}_{c}=1-\frac{c(\delta {T}_{\mathrm{max}}+{r}_{I}({\stackrel{\u2012}{T}}_{0}-{T}_{\mathrm{max}}))}{p\beta {T}_{\mathrm{max}}{\stackrel{\u2012}{T}}_{0}},$$

(2)

where *T‾*_{0} represents the level of uninfected hepatocytes before infection [5,9]. The critical drug efficacy is defined such that if *ε* ≥ε_{c}, virus levels continually decline on therapy ultimately leading to eradication, whereas if *ε*<ε_{c} viral loads initially decline but ultimately they stabilize at a new steady state despite continued therapy. As shown in sections 2.4 and 3.3 of [4], when ε >ε_{c}, after an initial rapid first phase viral decline that depends on *c* and *ε* (Fig. 1; [6]), and possible transient dynamics such as a shoulder phase (Fig. 1), the viral load ultimately declines in a final phase with slope

$$\lambda =\delta W$$

(3)

where

$$W=[1-\frac{1}{\delta}(\frac{(1-\epsilon )p\beta {\stackrel{\u2012}{T}}_{0}}{c}+{r}_{I}(1-\frac{{\stackrel{\u2012}{T}}_{0}}{{T}_{\mathrm{max}}}))].$$

One can show that 0 < *W* < 1, because of the condition ε >ε_{c} [4]. Thus when ε >ε_{c}, λ<δ.

We examined the relationship among the drug effectiveness, *ε*, the theoretical final phase slope, *λ*, δ, and the baseline fraction of infected cells, π, for 1,000 “in-silico” patients with viral kinetic parameters chosen at random within biologically realistic ranges (Online Supplementary Material). We found that when *ε*<99%, larger π is associated with up to ~10-fold inaccurate estimates of *δ* (Figs. S1A and S1B). That is, with weak drug effectiveness, HCV production from infected cells slows the decline of HCV RNA and therefore λ represents only a minimal estimate of *δ*. Further, high π tends to be generated when β, i.e. viral infectivity, is high and/or proliferation of infected cells is high, and hence high π may indicate patients in whom high de-novo infection is occurring during low efficacy treatment. However, when *ε*>99%, *λ*/*δ* is close to 1 irrespective of π (Fig. S1D and S1E). We illustrate our findings for 3 in-silico patients (Fig. 1). In addition, when ε>99% one can estimate δ with good accuracy directly from the final phase viral decline slope (λ_{estimated}) via linear regression of the kinetic data for both biphasic and triphasic declines (Fig. 1).

Previous models for HCV dynamics during antiviral therapy do not account for proliferation of both uninfected and infected hepatocytes (see review [12]). Moreover, to explain the biphasic viral decline observed over a short period of time (14 days), Neumann et al. [6] assumed that the target cell population remained constant. This approximation allowed them to solve the biphasic viral decay analytically (Eq. 5 from Neumann et al. [6]). This solution was used to estimate the infected cell loss rate (termed here *δ _{analytical}*), as well as other model parameters. We compared (Fig. 2)

Fitting standard models for HCV infection to patients’ HCV-RNA data during treatment with (PEG)-IFN alone or in combination with ribavirin (see review[12]) showed that the estimated infected cell loss rate (*δ*) is highly variable – from <0.01 day^{−1} [6] up to 0.49 day^{−1} [13] (corresponding to infected cells half-lives of ~1.4 days to >70 days). The mean effectiveness of high-daily dose interferon-α (with or without ribavirin), *ε*, in genotype-1 infected patients, is dose-dependent, ranging from approximately 79% to 99.7% [6]. With PEG-IFN plus ribavirin therapy, the average effectiveness *ε* is approximately 67%±30% [14] and in HCV/HIV coinfected patients the median weekly average effectiveness of PEG-IFN plus ribavirin was 48% with an interquartile range of 31% [15]. Thus, *ε*<99% is typical. Above we showed that by including proliferation of uninfected and infected hepatocytes in a model [5], the final phase slope may underestimate *δ* by as much as 10-fold under low interferon-α efficacies (*ε*<99%; Figs. Figs.11 and and2).2). However, when the initial viral drop is greater than 2 log (ε>99%), such as can be achieved with new and highly potent antiviral agents [16], we predict that the final phase slope is close to *δ* regardless, of π (Fig. S1).

The typical drop of HCV RNA under treatment is biphasic [12]. According to our recent predictions [5], patients who exhibit a biphasic HCV-RNA decay during treatment have a lower percentage of hepatocytes that are HCV-infected, π. Interestingly, while Agnello et al. [17] showed that a high percentage (3% to 83%) of hepatocytes harbor negative-strand HCV RNA (i.e., HCV replicative intermediates) both in HCV-infected patients and chimpanzees, others [18] have found only a low percentage (4% to 25%) in patients with HCV. If indeed, the majority of patients in whom a biphasic pattern is observed have a small *π* then according to our results (Fig. S1), the estimated HCV-infected cell loss rate, *δ*_{analytical}, obtained using the analytical model [6], with *ε* <99% is close to the actual one (e.g., Fig. 1A, B and and2C)2C) and can reliably be used. It should be noted that in treated patients with ε<99%, better assays to measure the percentage of HCV-infected hepatocytes are needed to estimate the infected cell loss rate with confidence.

A recent report by Neumann et al. [19] indicates that in patients treated with PEG-IFN plus telaprevir, ε>99% and the second-phase slope is significantly higher than previous estimates with (PEG)-IFN alone (or in combination with ribavirin). Our findings (cf., Fig 1) are consistent with this observation and provide a basis for understanding why the second-phase slope in patients treated with new, highly potent antiviral agents is higher than under the standard (PEG)-IFN (with or without ribavirin) therapy.

We have shown that in patients with treatments achieving ε > 99% the final phase slope can be used to accurately estimate the infected cell loss rate. In order to access the role of the immune response in eliminating virally-infected cells accurate estimates of δ are required. Our work shows how these estimates should be attained.

Portions of this work was done under the auspices of the U. S. Department of Energy under contract DE-AC52-06NA25396 and supported by NIH grants AI28433 and RR06555 (ASP). H.D is supported by the University of Illinois Gastrointestinal and Liver Disease (UIC GILD) Association.

1. NIH National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology. 2002;36:S3–20. [PubMed]

2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. [PubMed]

3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965. [PubMed]

4. Dahari H, Lo A, Ribeiro RM, Perelson AS. Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy. J Theor Biol. 2007;247:371–381. [PMC free article] [PubMed]

5. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology. 2007;46:16–21. [PubMed]

6. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282:103–107. [PubMed]

7. Dahari H, Major M, Zhang X, et al. Mathematical modeling of primary hepatitis C infection: Noncytolytic clearance and early blockage of virion production. Gastroenterology. 2005;128:1056–1066. [PubMed]

8. Theise ND, Nimmakayalu M, Gardner R, et al. Liver from bone marrow in humans. Hepatology. 2000;32:11–16. [PubMed]

9. Dahari H, Shudo E, Ribeiro RM, Perelson AS. Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology. 2008 in press. [PubMed]

10. Wein LM, D’Amato RM, Perelson AS. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J Theor Biol. 1998;192:81–98. [PubMed]

11. Callaway DS, Perelson AS. HIV-1 infection and low steady state viral loads. Bull Math Biol. 2002;64:29–64. [PubMed]

12. Perelson AS, Herrmann E, Micol F, Zeuzem S. New kinetic models for the hepatitis C virus. Hepatology. 2005;42:749–754. [PubMed]

13. Ribeiro RM, Layden-Almer J, Powers KA, Layden TJ, Perelson AS. Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology. 2003;38:509–517. [PubMed]

14. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37:1351–1358. [PubMed]

15. Talal AH, Ribeiro RM, Powers KA, et al. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology. 2006;43:943–953. [PubMed]

16. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology. 2007;46:631–639. [PubMed]

17. Agnello V, Abel G, Knight GB, Muchmore E. Detection of widespread hepatocyte infection in chronic hepatitis C. Hepatology. 1998;28:573–584. [PubMed]

18. Chang M, Marquardt AP, Wood BL, et al. In situ distribution of hepatitis C virus replicative-intermediate RNA in hepatic tissue and its correlation with liver disease. J Virol. 2000;74:944–955. [PMC free article] [PubMed]

19. Neumann AU, Rozenberg L, Reesink H, Zeuzem S, Chu HM. Novel mode of viral decline during telaprevir (VX-950) and PEG-IFN combination treatment predicted by a new combined intracellular and cellular hepatitis C viral dynamics model; 42nd Annual Meeting of the European Association for the Study of the Liver; Barcelona, Spain. 11-15 April 2007; Abstract S236 in J Hepatology 2007, 46.

PubMed Central Canada is a service of the Canadian Institutes of Health Research (CIHR) working in partnership with the National Research Council's national science library in cooperation with the National Center for Biotechnology Information at the U.S. National Library of Medicine(NCBI/NLM). It includes content provided to the PubMed Central International archive by participating publishers. |